Statistics from Altmetric.com
We read with genuine interest the original case reported by Chan and Bass1 in response to our paper describing musculoskeletal immune-related adverse events (irAE) related to cancer immunotherapy.2
Immune checkpoint inhibitors (ICI) represent an exciting new standard of care in selected advanced cancers and are being actively investigated in others. Unfortunately, only a subset of patients benefit from ICI and the current challenge is to transform the majority of non-responders to responders.3 This will likely be improved by combining ICI with other treatment strategies such as small molecules.
Two MEK inhibitors, trametinib and cobimetinib, are …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.